Zelira Therapeutics Limited (ZLD.AX) Comparison with companies in other sectors?

Zelira Therapeutics Limited has a share price of 11.90M. You can analyze Zelira Therapeutics Limited (ZLD.AX) competitors across different market sectors through stock heatmaps.

What are ZLD.AX's NET and operating margins?

Zelira Therapeutics Limited (ZLD.AX) operating margin is around -108.77, and net profit margin is approximately -118.50 as of the latest reports.

In what way does ZLD.AX's earnings per share (EPS) trend reflect its financial momentum?

Zelira Therapeutics Limited (ZLD.AX) EPS is -0.42 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Zelira Therapeutics Limited is -0.98, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Zelira Therapeutics Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Zelira Therapeutics Limited like P/E which is -0.96, P/B which is -0.55, and PEG which is -0.01. Compare them with sector averages to evaluate if the stock is priced fairly.

Zelira Therapeutics Limited

ZLD.AX•ASX

Healthcare

Biotechnology

A$0.41

A$0.00(0.00%)

Zelira Therapeutics Limited (ZLD.AX) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.42

P/E Ratio

-0.98

ROE

0.75%

Net Margin

-118.50%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$4.88M

Shares OutstandingTotal number of shares issued

$11.90M

Book Value/ShareNet worth per share

$-0.70

Revenue/ShareAnnual revenue per share

$0.004

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.42

Net MarginNet income as percentage of revenue

-11849.86%

Operating MarginOperating income as percentage of revenue

-10876.80%

ROEReturn on shareholders' equity

75.02%

ROAReturn on total assets

-203.10%

ROCEReturn on capital employed

56.33%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.47

Cash/ShareCash and equivalents per share

$0.003

FCF YieldFree cash flow as percentage of market cap

-108.41%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ZLD.AXFinancial Ratios Analysis details for ZLD.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ZLD.AXSector Benchmarking details for ZLD.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Zelira Therapeutics Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Zelira Therapeutics Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Zelira Therapeutics Limited's unique business strengths and challenges.

Key Financial Metrics for Zelira Therapeutics Limited

For Zelira Therapeutics Limited, essential financial indicators include EPS -0.42, PE -0.98, and ROE 0.75. These key ratios reveal insights into Zelira Therapeutics Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Zelira Therapeutics Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Zelira Therapeutics Limited

Metrics like Net Margin -11849.86% and ROA -203.10% shed light on how well Zelira Therapeutics Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Zelira Therapeutics Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Zelira Therapeutics Limited

Using ratios such as P/B Ratio -0.55 and PEG Ratio -0.01, investors can assess whether Zelira Therapeutics Limited is appropriately valued based on its financials and growth potential. These figures, combined with Zelira Therapeutics Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Zelira Therapeutics Limited

Financial health indicators, such as Debt/Equity Ratio -0.75 and Cash Flow $-0.47, provide a snapshot of Zelira Therapeutics Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Zelira Therapeutics Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Zelira Therapeutics Limited

Investing in Zelira Therapeutics Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Zelira Therapeutics Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;